Composite binding site drugs

Details Composite binding site drugs Composite binding site drugs

1989-05-15

1991-12-17

Moskowitz, Margaret

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 8, 530303, C07K 740, A61K 3726, A61K 3702

Patent

active

050735403

ABSTRACT:
Methods and compositions are provided for regulating surface membrane receptor response by providing novel proteinaceous compositions to bind to two separate sites of a surface membrane receptor, the binding site of the receptor and an allosteric site, which binds to a sequence of a Class I MHC antigen. The resulting products may act as agonist or antagonist to the normal function of the receptor and find use in the control of physiological processes.

REFERENCES:
patent: 4478823 (1984-10-01), Sanderson
patent: 4761371 (1988-08-01), Bell et al.
Watts et al., Journal of Immunology, vol. 139, 3878-3885, No. 11, 12/01/87 Lenninger Biochemistry, 2nd Edition, p. 109, 1978.
"The Human Insulin Receptor cDNA: The Structural Basis for Hormone-Activated Transmembrane Signalling," by Ebina et al., in Cell (1985), 40:747-758.
"Human Insulin Receptor and Its Relationship to the Tyrosine Kinase Family of Oncogenes," by Ullrich et al., in Nature (1985), 313:756-761.
"Interaction Between Major Histocompatibility Complex Antigens and Epidermal Growth Factor Receptors on Human Cells" by Schreiber et al. in The Journal of Cell Biology (1984), 98:725-731.
"Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells," by Ullrich et al., in Nature (1984), 309:418-425.
"The Original Function of MHC Antigens as the General Plasma Membrane Anchorage Site of Organogenesis-Directing Proteins," by S. Ohno in Immunol. Rev. (1977), 33:59-69.
"Possible Roles of Compound Membrane Receptors in the Immune System" by Simonsen and Olsson in Ann. Immunol. (1983), 134(d):85-92.
"Molecular Association Between Major Histocompatibility Complex Class I Antigens and Insulin Receptors in Mouse Liver Membranes" by Fehlmann et al. in Proc. Natl. Acad. Sci. USA (1985), 82:8634-8637.
"The Structure of Insulin Receptor and Its Subunits" by Kasuga et al. in The Journal of Biological Chemistry (1982), 257:10392-10399.
"The Major Histocompatibility Complex Class I Heavy Chain as a Structural Subunit of the Human Cell Membrane Insulin Receptor: Implications for the Range of Biological Functions of Histocompatibility Antigens:" by Due et al. in Proc. Natl. Acad. Sci. USA (1986), 83:6007-6011.
"Class I Histocompatibility Antigens and Insulin Receptors: Evidence for Interactions" by Phillips et al. in Proc. Natl. Acad. Sci. USA (1986), 83:3474-3478.
"Cross-Linking of Insulin Receptors to MHC Antigens in Human B Lymphocytes: Evidence for Selective Molecular Interactions" by Samson et al. in The Journal of Immunology (1986), 137(7):2293-2298.

Affiliated with

Also associated with

Rating

Composite binding site drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composite binding site drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composite binding site drugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-835642